These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16052194)

  • 1. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
    Green LW
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiovascular disease in those aged 55 years and over controlled with a combined pill against 4 risk factors: some brief comments].
    Rabelink TJ
    Ned Tijdschr Geneeskd; 2003 Aug; 147(32):1537-8. PubMed ID: 12942841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 7. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
    Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
    Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
    Franco OH; Karnik K; Bonneux L
    Horm Metab Res; 2007 Sep; 39(9):627-31. PubMed ID: 17846968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
    Wald DS; Wald NJ
    J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits, challenges, and registerability of the polypill.
    Sleight P; Pouleur H; Zannad F
    Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single pill for prevention?
    Harv Heart Lett; 2009 Jul; 19(11):6. PubMed ID: 19927382
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.
    Kasliwal RR; Bansal M; Mehrotra R; Agrawal V; Shrivastava S
    Indian Heart J; 2010; 62(4):324-9. PubMed ID: 21280473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.